But ....
Everyone in this study is "high risk" and has a comorbidity. Hence, your assertion cannot be correct, as the pre-release of top line results state there was a difference between tofa and adalimumab.
More importantly, we have been waiting for many months for Pfizer and the FDA to finalize and publish their full analysis - we need to wait till then to know if your statement is true or not.
Like you, Im awaiting these results as it may change future treatment of RA patients. Thanks for your thoughtful comment.